公开(公告)号：US20160258940A1

公开(公告)日：2016-09-08

申请号：US15029462

申请日：2014-10-17

Applicant: IMRA AMERICA, INC. ,  JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Yuki ICHIKAWA ,  Kiyotaka SHIBA

IPC: G01N33/543 ,  G01N33/574 ,  G01N33/553 ,  A61K49/00

CPC classification number: G01N33/54346 ,  A61K9/14 ,  A61K38/10 ,  A61K47/02 ,  A61K47/10 ,  A61K49/0004 ,  G01N33/553 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57492 ,  G01N33/587 ,  G01N2333/705 ,  G01N2333/82

Abstract: Provide is a stable metallic nanostructure that causes no aggregation when surface-modified with biomolecule-reactive functional molecules. 30 to 90% of the surface of the metallic nanostructure is covered with at least one or more types of colloid-stabilizing functional molecules. Furthermore, the metallic nanostructure is covered with one or more types of biologically functional molecules.

Abstract translation: 提供一种稳定的金属纳米结构，当用生物分子反应性功能分子进行表面改性时，不会引起聚集。 金属纳米结构表面的30-90％被至少一种或多种胶体稳定功能分子覆盖。 此外，金属纳米结构被一种或多种类型的生物功能分子覆盖。

公开(公告)号：US20210100884A1

公开(公告)日：2021-04-08

申请号：US17121818

申请日：2020-12-15

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  THE JIKEI UNIVERSITY

Inventor： Masaki ITO ,  Kiyotaka SHIBA

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

公开(公告)号：US20210100885A1

公开(公告)日：2021-04-08

申请号：US17121823

申请日：2020-12-15

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  THE JIKEI UNIVERSITY

Inventor： Masaki ITO ,  Kiyotaka SHIBA

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

公开(公告)号：US20160166665A1

公开(公告)日：2016-06-16

申请号：US14901384

申请日：2014-06-30

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  THE JIKEI UNIVERSITY

Inventor： Masaki ITO ,  Kiyotaka SHIBA

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/62 ,  A61K2039/64 ,  C07K14/4748 ,  C07K14/70539 ,  Y02A50/412

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract translation: 公开了能诱导足够高的细胞介导免疫的新型疫苗。 本发明的疫苗作为有效成分含有包含串联重复结构的多肽，其中源自抗原蛋白质的MHC I类表位区域和间隔区序列交替地和重复地相互连接至少三次， 或包含编码所述多肽并且能够在体内表达所述多肽的多核苷酸的重组载体。 间隔序列例如是作为不可避免地由单碱基序列编码的氨基酸序列产生的序列，其被设计为使得衍生自抗原蛋白的MHC I类表位区域，源自抗原的MHC II类表位区域 蛋白质，并且至少一个高级结构稳定区域由所述单碱基序列中的不同阅读框编码。